3D modelling method and application to a digital campus by fusing point cloud data and image data.

Objective: The use of single-source data for real-world 3D modelling currently faces problems such as deformation, pulling and fuzzy texture at the bottom of buildings in some feature models because of the lack of images. Moreover, LIDAR generates a huge amount of data, and the massive raw data processing and point cloud parsing puts high demands on the hardware arithmetic and algorithms. Aiming at the deficiencies and defects of the two data sources of inclined photogrammetry and airborne laser point cloud in the construction of high-quality and high-precision city-level 3D models. Methods: this study uses a university library building as an example and proposes the main technical process and method of modelling after fusing the point cloud data acquired by inclined photogrammetry and 3D laser scanning technology. This is accomplished in the reconstruction stage of multi-source data fusion through data spatial alignment, coordinate system unification and data spatial integration. At the stage of multi-source data fusion and reconstruction, through data spatial alignment, coordinate system unification, point cloud coarse alignment and the iterative closest point (ICP) algorithm, a realistic 3D model of a building is constructed to verify the effectiveness of the modelling method. Results: The method can effectively improve the accuracy of the real-life 3D model, repair the deficiencies in the model and optimise the details of the model. It can also significantly improve the fineness of the tilt photography model and perfectly present the geometric and texture information of the building, making it a superior method for fine 3D reconstruction. Conclusion: This 3D reconstruction method of buildings, which integrates low-altitude inclined photogrammetry and airborne light detection and ranging (LiDAR), has high positional accuracy and can provide new methods and new ideas for the construction of digital campuses as well as for other engineering applications.

Saponin â from Shuitianqi () inhibits metastasis by negatively regulating the transforming growth factor-ß1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg's Albino/c mouse model.

OBJECTIVE: To examine the influence of Saponin I from Shuitianqi (Rhizoma Schizocapasae Plantagineae) (SSPH I) on hepatocellular carcinoma (HCC) metastasis, and to elucidate the underlying mechanism. METHODS: The intrahepatic metastasis Bagg's Albino/c (BALB/c) mouse model was established with human hepatocellular carcinomas (HepG2) cells, then treated with normal saline (once per day), cisplatin (2 mg/kg, once every 2 d), and SSPH Ⅰ (25, 50, and 75 mg/kg, once per day). Then, we assessed alterations in the hepatic pathology and target protein expressions in the intrahepatic metastasis BALB/c mouse model using a series of molecular biology techniques. RESULTS: Based on our analysis, SSPH Ⅰ significantly alleviated hepatocyte necrosis and tumor cells infiltration. Moreover, SSPH Ⅰ suppressed extracellular matrix (ECM) degradation and angiogenesis viaa decrease in matrix etalloproteinase-2 (MMP-2), MMP-9, CD31, CD34, and vascular endothelial growth factor (VEGF) levels. Furthermore, SSPH Ⅰ repressed invasion and meta-stasis by suppressing the transforming growth factor-ß1 (TGF-ß1)/Smad7 axis and epithelial-mesenchymal transition (EMT), as evidenced by the scarce TGF-ß1, N-cadherin, and Vimentin expressions, and elevated Smad7 and E-cadherin expressions. CONCLUSION: The SSPH Ⅰ-mediated negative regulation of the TGF-ß1/Smad7 axis and EMT are critical for the inhibition of HCC invasion and metastasis.

Guilingji capsule for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial.

OBJECTIVE: To investigate the effectiveness and safety of Guilingji capsule (, GLJC) in treatment of Alzheimer's disease (AD) patients with kidney-marrow deficiency pattern (KMDP) compared with gingko extract tablets. METHODS: This is a secondary analysis of a large-scale multicenter randomized non-inferiority clinical trial. A total of 120 AD patients with KMDP were enrolled in this study. The participants were randomly categorized into two groups: (a) GLJC group ( = 60) and (b) gingko group ( = 60). The GLJC group was treated with GLJC and gingko extract mimetic tablets, whereas the gingko group received gingko extract tablets and mimetic GLJC. The data on the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Activities of Daily Living (ADL), and Chinese Medicine Symptom Scale (CM-SS) was evaluated at 0, 12, and 24 weeks of treatment. The serum levels of acetylcholine (Ach), acetylcholinesterase (AchE), B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein (Bax) in the participants were measured before and after 24 weeks of treatment. The safety was based on the incidence of adverse events. RESULTS: Both interventions significantly increased the MMSE scores of the participants and decreased their ADAS-Cog, ADL, and CM-SS scores ( < 0.01). Compared with the gingko group, the GLJC group had a higher effective rate of improvement in the symptoms of "amnesia" and "dull expression and slow thinking" at the 12th week and 24th week ( < 0.05, < 0.01). In the GLJC group, serum Bcl-2 levels were significantly increased at the 24th week ( < 0.05). Serum Bax and AchE levels of the two groups were significantly decreased at the 24th week ( < 0.01). No treatment-related adverse events were reported in the two groups. CONCLUSIONS: GLJC is equivalent to the gingko extract tablets in terms of improving cognitive function and the quality of life in AD patients with KMDP and has good clinical efficacy and safety. When it comes to improving TCM symptoms and anti-aging, GLJC is even more advantageous.

[Pharmacokinetics of praziquantel injection in healthy buffaloes].

Objective To investigate the pharmacokinetics and relative bioavailability of praziquantel injection in buffaloes in contrast to praziquantel tablet. Methods A single oral administration of praziquantel tablet at a dose of 20 mg/kg or intramuscular administration of praziquantel injection at a dose of 10 mg/kg was performed in six healthy adult buffalos according to a twoperiod crossover design. The praziquantel concentration in plasma was determined by a high performance liquid chromatography (HPLC) method. The pharmacokinetic parameters were calculated by non-compartmental analysis. Results The main pharmacokinetic parameters of praziquantel tablet were as follows: Tmax = (0.60±0.29)h, Cmax = (0.57±0.37)µg/ml, T1/2ß = (0.70±0.42)h, AUC = (0.80±0.70) (µg/ml)·h. The main pharmacokinetic parameters of praziquantel injection were as follows: Tmax = (0.65± 0.49)h, Cmax = (3.82±1.17)µg/ml, T1/2ß = (1.00±0.73)h, AUC = (1.61±0.89) (µg/ml)·h. The relative bioavailability of praziquantel injection was 402.5% in contrast to praziquantel tablet. Conclusion The praziquantel injection has pharmacokinetic characteristics of rapid absorption, high bioavailability and extensive distribution, and the clinical recommended dosage of praziquantel injection is 10 mg/kg.